Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Resection of Retroperitoneal Sarcoma ("RESQU-SARC" Trial)

Next Previous
Trial Profile

Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Resection of Retroperitoneal Sarcoma ("RESQU-SARC" Trial)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Perioperative pain; Postoperative pain
  • Focus Therapeutic Use
  • Acronyms RESQU-SARC

Most Recent Events

  • 13 Nov 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
  • 13 Nov 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2026.
  • 21 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top